Rules concerning license and screening of biological preparations, etc. revised

The Korea Food and Drug Administration announced on May 23 that it revised rules concerning license and screening of biological preparations and biotechnology based drugs so as to separate these items from OTC products defined in the same category.

The KFDA explained that under the newly revised rules, any drug maker, who developed a biotechnology based drug with new concepts that can been c...